New drug shows promise for rare, hard-to-treat cancers
NCT ID NCT05024968
First seen Feb 26, 2026 · Last updated Apr 24, 2026 · Updated 6 times
Summary
This study tested a drug called sintilimab in 10 people with advanced cancer of unknown primary (CUP) that had not responded to standard chemotherapy. Sintilimab is an immunotherapy that helps the immune system attack cancer cells. The goal was to see if the drug could shrink tumors and control the disease for as long as possible, but it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.